Patents by Inventor J. Fraser Glickman

J. Fraser Glickman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrido[4,3-b]indoles and azepino[4,5-b]indoles as inhibitors of cGAS
    Patent number: 11414422
    Abstract: 1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: August 16, 2022
    Assignee: The Rockefeller University
    Inventors: Lodoe Lama, Thomas Tuschl, Daisuke Tomita, Dinshaw Patel, J. Fraser Glickman, Taku Kamei, Michael Miller, Yasutomi Asano, Rei Okamoto, Shogo Hashizume, Jumpei Aida, Toshihiro Imaeda, Mayako Michino, Takanobu Kuroita
  • INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS
    Publication number: 20220185812
    Abstract: Tri-cyclyl nitrogen-containing heterocyclic compounds are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
    Type: Application
    Filed: March 12, 2020
    Publication date: June 16, 2022
    Applicants: The Rockefeller University, Memorial Sloan-Kettering Cancer Center
    Inventors: Daisuke TOMITA, Lodoe LAMA, Thomas TUSCHL, Dinshaw PATEL, J. Fraser GLICKMAN, Taku KAMEI, Michael MILLER, Yasutomi ASANO, Rei OKAMOTO, Shogo HASHIZUME, Jumpei AIDA, Toshihiro IMAEDA, Mayako MICHINO, Takanobu KUROITA
  • 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4, 3-b]INDOLE INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES
    Publication number: 20210155625
    Abstract: 1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
    Type: Application
    Filed: February 5, 2019
    Publication date: May 27, 2021
    Applicants: The Rockefeller University, Memorial Sloan-Kettering Cancer Center
    Inventors: Lodoe LAMA, Thomas TUSCHL, Daisuke TOMITA, Dinshaw PATEL, J. Fraser GLICKMAN, Taku KAMEI, Michael MILLER, Yasutomi ASANO, Rei OKAMOTO, Shogo HASHIZUME, Jumpei AIDA, Toshihiro IMAEDA, Mayako MICHINO, Takanobu KUROITA
  • Fluorescent capture assay for kinase activity employing an anti-phosphotyrosine antibody as both the capture agent and detecting agent
    Patent number: 6806056
    Abstract: A method for determining the level of tyrosine kinase activity in a biological sample is disclosed. The method employs an anti-phosphotyrosine antibody as both the capture agent and the detecting agent. The detecting antibody is labeled with a fluorescent label, for instance, Cy5, Cy5.5 or Cy7 or a lanthanide ion, such as europium, as the signal generating entity. The method is particularly well suited to high throughput screening, for example, for compounds which modulate tyrosine kinase activity.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: October 19, 2004
    Assignee: Pharmacopeia Drug Discovery, Inc.
    Inventors: J. Fraser Glickman, James Inglese, Bassam Damaj, Maria L. Webb, Jonathan J. Burbaum
  • Fluorescent capture assay for kinase activity
    Publication number: 20020177179
    Abstract: A method for determining the level of tyrosine kinase activity in a biological sample is disclosed. The method employs an anti-phosphotyrosine antibody as both the capture agent and the detecting agent. The detecting antibody is labeled with a fluorescent label, for instance, Cy5, Cy5.5 or Cy7 or a lanthanide ion, such as europium, as the signal generating entity. The method is particularly well suited to high throughput screening, for example, for compounds which modulate tyrosine kinase activity.
    Type: Application
    Filed: April 18, 2002
    Publication date: November 28, 2002
    Applicant: Pharmacopiea, Inc.
    Inventors: J. Fraser Glickman, James Inglese, Bassam Damaj, Maria L. Webb, Jonathan J. Burbaum
  • Fluorescent capture assay for kinase activity employing anti-phosphotyrosine antibodies as capture and detection agents
    Patent number: 6406869
    Abstract: A method for determining the level of tyrosine kinase activity in a biological sample is disclosed. The method employs an anti-phosphotyrosine antibody as both the capture agent and the detecting agent. The detecting antibody is labeled with a lanthanide ion, such as europium, as the signal generating entity. The method is particularly well suited to high throughput screening, for example, for compounds which modulate tyrosine kinase activity.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: June 18, 2002
    Assignee: Pharmacopeia, Inc.
    Inventors: J. Fraser Glickman, James Inglese, Bassam Damaj
  • FLUORESCENT CAPTURE ASSAY FOR KINASE ACTIVITY EMPLOYING ANTI-PHOSPHOTYROSINE ANTIBODIES AS CAPTURE AND DETECTION AGENTS
    Publication number: 20020068308
    Abstract: A method for determining the level of tyrosine kinase activity in a biological sample is disclosed. The method employs an anti-phosphotyrosine antibody as both the capture agent and the detecting agent. The detecting antibody is labeled with a lanthanide ion, such as europium, as the signal generating entity. The method is particularly well suited to high throughput screening, for example, for compounds which modulate tyrosine kinase activity.
    Type: Application
    Filed: October 22, 1999
    Publication date: June 6, 2002
    Inventors: J. FRASER GLICKMAN, JAMES INGLESE, BASSAM DAMAJ